InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,283.40
(
0.00%
)
US TECH 100
18,071.60
(
-0.30%
)
Dow Jones
38,571.03
(
0.00%
)
Brent Oil
77.13
(
-1.30%
)
Bitcoin
68,951.21
(
0.21%
)
Post# of 252036
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119753
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 182906

Thursday, 02/26/2015 7:49:32 PM

Thursday, February 26, 2015 7:49:32 PM

Post# of 252036
VTAE -23% AH on safety halt for B-I’s BACE drug:

http://finance.yahoo.com/news/bace-inhibitor-bi-1181181-voluntarily-211000710.html

Vitae Pharmaceuticals, Inc. today announced that its partner Boehringer Ingelheim has voluntarily placed BI 1181181 on a temporary clinical hold, and has notified regulatory agencies of its decision. BI 1181181 is an orally-active beta secretase (BACE) inhibitor being evaluated in Phase 1 clinical trials for the treatment and prevention of Alzheimer's disease. This action was taken to further investigate skin reactions observed in some study participants during the multiple rising dose trial.

Note: VTAE (Vitae) should not be confused with the recent IPO, NVTA (Invitae).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up